Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice (Q39645753)

13 September 2017

title

Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice (English)

1 reference

13 September 2017

0 references

Shigeru Yoshida

1

1 reference

13 September 2017

Takahide Ohishi

2

1 reference

13 September 2017

Tetsuo Matsui

3

1 reference

13 September 2017

Hirotsugu Tanaka

4

1 reference

13 September 2017

Hiroyuki Oshima

5

1 reference

13 September 2017

Yasuhiro Yonetoku

6

1 reference

13 September 2017

Masayuki Shibasaki

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

16 October 2010

1 reference

full work available at URL

13 September 2017

https://api.elsevier.com/content/article/PII:S0006291X10018668?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

https://api.elsevier.com/content/article/PII:S0006291X10018668?httpAccept=text/plain

31 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Biochemical and Biophysical Research Communications

31 July 2024

published in

1 reference

13 September 2017

volume

402

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

280-285

1 reference

Pathogenesis of NIDDM. A balanced overview

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

31 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies

31 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

31 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Incretin-based therapies: viewpoints on the way to consensus

31 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

31 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

DPP4 inhibitors: a new approach in diabetes treatment

31 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Incretin-based therapies in type 2 diabetes mellitus

31 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor

31 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells

31 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

31 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release

31 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

31 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

GPR119 agonists for the treatment of type 2 diabetes

31 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion

31 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Isolation of pancreatic islets and primary culture of the intact microorgans or of dispersed islet cells

31 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Postprandial glucose regulation: new data and new implications

31 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

31 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

31 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.

31 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell

31 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders

31 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BBRC.2010.10.015

31 July 2024

Identifiers

1 reference

13 September 2017

1 reference